| PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ... Journal of clinical oncology 27 (16), 2622-2629, 2009 | 510 | 2009 |
| A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors I Petrini, PS Meltzer, IK Kim, M Lucchi, KS Park, G Fontanini, J Gao, ... Nature genetics 46 (8), 844-849, 2014 | 263 | 2014 |
| PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC M Del Re, R Marconcini, G Pasquini, E Rofi, C Vivaldi, F Bloise, ... British journal of cancer 118 (6), 820-824, 2018 | 241 | 2018 |
| Thymic malignancies: from clinical management to targeted therapies RJ Kelly, I Petrini, A Rajan, Y Wang, G Giaccone Journal of clinical oncology 29 (36), 4820-4827, 2011 | 173 | 2011 |
| MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non–small cell lung carcinoma J Voortman, A Goto, J Mendiboure, JJ Sohn, AJ Schetter, M Saito, ... Cancer research 70 (21), 8288-8298, 2010 | 171 | 2010 |
| Biology of MET: a double life between normal tissue repair and tumor progression I Petrini Annals of translational medicine 3 (6), 2015 | 162 | 2015 |
| Mutations of epigenetic regulatory genes are common in thymic carcinomas Y Wang, A Thomas, C Lau, A Rajan, Y Zhu, JK Killian, I Petrini, T Pham, ... Scientific reports 4 (1), 7336, 2014 | 141 | 2014 |
| The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer HR Fernandez, SM Gadre, M Tan, GT Graham, R Mosaoa, MS Ongkeko, ... Cell Death & Differentiation 25 (7), 1239-1258, 2018 | 98 | 2018 |
| Contribution of KRAS mutations and c. 2369C> T (p. T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA M Del Re, M Tiseo, P Bordi, A D'Incecco, A Camerini, I Petrini, M Lucchesi, ... Oncotarget 8 (8), 13611, 2017 | 97 | 2017 |
| Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma I Petrini, M Lencioni, M Ricasoli, M Iannopollo, C Orlandini, F Oliveri, ... Cancer chemotherapy and pharmacology 69, 773-780, 2012 | 90 | 2012 |
| Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy M Del Re, S Crucitta, G Gianfilippo, A Passaro, I Petrini, G Restante, ... International journal of molecular sciences 20 (16), 3951, 2019 | 81 | 2019 |
| Are MSCs angiogenic cells? New insights on human nestin-positive bone marrow-derived multipotent cells S Pacini, I Petrini Frontiers in cell and developmental biology 2, 20, 2014 | 80 | 2014 |
| Expression and mutational status of c-kit in thymic epithelial tumors I Petrini, PA Zucali, HS Lee, MA Pineda, PS Meltzer, B Walter-Rodriguez, ... Journal of Thoracic Oncology 5 (9), 1447-1453, 2010 | 79 | 2010 |
| Insulin‐like growth factor‐1 receptor and phosphorylated AKT‐serine 473 expression in 132 resected thymomas and thymic carcinomas PA Zucali, I Petrini, E Lorenzi, M Merino, L Cao, L Di Tommaso, HS Lee, ... Cancer 116 (20), 4686-4695, 2010 | 78 | 2010 |
| Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors I Petrini, PS Meltzer, PA Zucali, J Luo, C Lee, A Santoro, HS Lee, ... Cell death & disease 3 (7), e351-e351, 2012 | 77 | 2012 |
| Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing E Katsman, S Orlanski, F Martignano, I Fox-Fisher, R Shemer, Y Dor, ... Genome Biology 23 (1), 158, 2022 | 63 | 2022 |
| Detection of ALK and KRAS mutations in circulating tumor DNA of patients with advanced ALK-positive NSCLC with disease progression during crizotinib treatment P Bordi, M Tiseo, E Rofi, I Petrini, G Restante, R Danesi, M Del Re Clinical lung cancer 18 (6), 692-697, 2017 | 61 | 2017 |
| Implications of KRAS mutations in acquired resistance to treatment in NSCLC M Del Re, E Rofi, G Restante, S Crucitta, E Arrigoni, S Fogli, M Di Maio, ... Oncotarget 9 (5), 6630, 2018 | 54 | 2018 |
| A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer E Vasile, G Masi, L Fornaro, S Cupini, F Loupakis, S Bursi, I Petrini, ... British journal of cancer 100 (11), 1720-1724, 2009 | 54 | 2009 |
| Lower airway inflammation before and after house dust mite nasal challenge: an age and allergen exposure-related phenomenon F Marcucci, G Passalacqua, GW Canonica, F Frati, S Salvatori, I Petrini, ... Respiratory medicine 101 (7), 1600-1608, 2007 | 50 | 2007 |
